Evidence map›Paper›PMID 37293083›Full record

ArticlebioRxiv : the preprint server for biology2023

Vaccine-mediated protection against merbecovirus and sarbecovirus challenge in mice.

David R Martinez, Alexandra Schafer, Tyler D Gavitt, Michael L Mallory, Esther Lee, Nicholas J Catanzaro, Haiyan Chen, Kendra Gully, Trevor Scobey, Pooja Korategere and 12 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 3 institutions in 3 countries.

David R MartinezDepartment of Immunobiology, Yale School of Medicine, New Haven, CT, 06510, USA.
Alexandra SchaferDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Tyler D GavittDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Michael L MalloryDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Esther LeeDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Nicholas J CatanzaroDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Haiyan ChenDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Kendra GullyDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Trevor ScobeyDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Pooja KorategereDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Alecia BrownDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Lena SmithDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Rob ParksDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Maggie BarrDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Amanda NewmanDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Cindy BowmanDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
John M PowersDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Katayoun MansouriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Robert J EdwardsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Ralph S BaricDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
Barton F HaynesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
Kevin O SaundersDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, 27710, USA.
International Vaccine Institute · KRUniversity of North Carolina at Chapel Hill · USYale University · US

Funding

Project 4: Computational panbetaCoV immunogen designP01AI158571 · NIAID · DUKE UNIVERSITY · PI HENDERSON, RORY · 2021 to 2023
$28.0M
Project 3: Serological Interactions with the Mucosal Innate Immune System Regulates COVID-19 Associated Tissue Damage.U54CA260543 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WOLFGANG, MATTHEW C · 2020 to 2024
$9.8M
NCI NIH HHS U54 CA260543NIAID NIH HHS P01 AI158571
6 · The paper itself

Abstract

The emergence of three distinct highly pathogenic human coronaviruses - SARS-CoV in 2003, MERS-CoV in 2012, and SARS-CoV-2 in 2019 - underlines the need to develop broadly active vaccines against the

Indexed as

bat coronavirusMERS-CoVnanoparticleneutralizationreceptor binding domainSARS-CoVSARS-CoV-2universal vaccine

Identifiers

PMID37293083
PMCPMC10245799
OpenAlexW4377694561

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.